We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > News > Policy > Content Piece

Alberta to Regulate Psychedelic-Assisted Therapy

By Leo Bear-McGuinness

Published: Oct 07, 2022   

Complete the form below and we will email you a PDF version of "Alberta to Regulate Psychedelic-Assisted Therapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alberta will become the first province in Canada to regulate psychedelic-assisted therapy.

In a notice published on Wednesday, October 5, the region’s government announced it had amended its Mental Health Services Protection regulations to include new policies on psychedelic-assisted therapy. These requirements will come into effect on January 16, 2023.

Under the new amendments, “only a psychiatrist or a physician in consultation with a psychiatrist can prescribe a psychedelic drug for the purposes of treating a psychiatric disorder, unless the drug is ketamine provided outside of psychedelic assisted psychotherapy.”

Other than for such ketamine-related reasons, psychiatrists will only be allowed to conduct psychedelic therapy in Alberta if they apply for a license under the Mental Health Services Protection Act.

Among other requirements, staff at a psycho-therapy clinic must supervise the patients while they are in an altered mental state and report any severe injuries or deaths immediately to the government.

Although psychedelics drugs like psilocybin, LSD, and ketamine are illegal in Canada, doctors and researchers can apply to Health Canada to use them in clinical trials or for therapeutic purposes. This request process was streamlined earlier this year following an amendment to Health Canada’s Special Access Program.

 

Like what you just read? You can find similar content on the topic tags shown below.

Policy Psychedelics

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement